GelAtlas, supported by NSTC, is a patented open-close hydrogel organ-on-a-chip. Its breakthrough lies in precision 3D-printed molds defining arbitrary geometries, achieving superior tissue localization and polarity control over traditional Dome cultures. Validated with breast cancer models, it supports over 30 days of cultivation and automated imaging. With a 100% non-destructive recovery rate, it provides a high-predictivity standard platform for New Approach Methodologies (NAMs).

GelAtlas＇s reversible architecture overcomes the conflict between stability and recovery, ensuring 100% recovery for precious specimens. Key innovations include: precision 3D-printed arbitrary microwells for spatial localization and polarity control; and modular expansion from single to 18-chamber chips. Validated with breast cancer models, it supports 30-day cultivation and automated imaging, providing a high-predictivity standard platform for New Approach Methodologies.

GelAtlas transforms organoid development into a highly reproducible, scalable process, aligning with the FDA Modernization Act 3.0 to provide standardized non-animal data for IND applications. Its 18-chamber modular throughput saves pharma and CROs over 60% in preclinical costs and reagents, building a resilient commercial moat with significant regulatory dividends and profitability.